


Cardiomyopathie de Tako-tsubo

Physiopathologie & Traitement



DESC de Réanimation Médicale

31 Mars 2024

Étudiante : Juliette P...

Tuteur : Pr Julien M...



Définition

Takotsubo is Japanese
for Octopus Trap

- = Cardiomyopathie de stress
- = Ballonisation apicale transitoire
- = « Broken heart » syndrome



Comment pêche-t-on la pieuvre ?

Pots en terre cuite laissés
plusieurs jours dans
fond marin

Les pieuvres s'en
servent comme d'





竹筒
蛸島
罎

Quand les pots sont remontés à la surface, elles ne cherchent pas à s'échapper et se plaquent contre la paroi


高三寸五分
野田作
昭和六年六月四日





矢平
目



七



Épidémiologie



Épidémiologie

Characteristics	General admissions, n (%)	TTC, n (%)
General admissions	33 506 402	6837
Age		
<34	6 556 830 (19.6)	127 (1.9)
35-49	5 588 174 (16.7)	581 (8.5)
50-64	7 382 129 (22)	1975 (28.9)
65-79	8 038 673 (24)	2952 (43.2)
80	5 963 187 (17.8)	1202 (17.6)
Sex		
Male	13 271 083 (39.7)	660 (9.7)
Female	20 173 088 (60.3)	6178 (90.4)
Ethnicity		
White	18 957 769 (56.5)	4606 (67.4)
Black	3 445 928 (10.3)	300 (4.4)
Hispanic	2 638 251 (7.9)	298 (4.3)
Asian	680 357 (2.0)	76 (1.1)
Native American	173 273 (0.5)	43 (0.6)
Others	882 716 (2.6)	103 (1.5)
Unknown	6 750 699 (20.1)	1413 (20.7)
Comorbidities		
Ischemic heart disease	787 814 (2.4)	151 (2.2)



0.05 using χ^2 test. See text for details.

8,8

Hommes + 55 ans **10,7** > Hommes - 55 ans

Hommes + 55 ans **4,8** > Femmes - 55 ans


Wink et al., Am Heart J, 2012



Diagnostic : principal diagnostic différentiel : SCA


- Clinique :
 - Douleur thoracique +++ : mime un SCA
Dyspnée, palpitations, asthénie

- ECG




ECG : véritable aide au diagnostic ?


Takotsubo cardiomyopathy



Anterior wall STEMI



B



Présentation clinique atypique : atteinte du VD

Table 1. Echocardiographic Data and Complications Incurred for Patients Without and With RV Involvement

	Patients With No RV Involvement	Patients With RV Involvement	P Value
n	17	8	
Age (\pm SD), yrs	72 (\pm 11)	70 (\pm 13)	0.76
Presentation LV ejection fraction (\pm SD)	42 (\pm 14)	29 (\pm 9)	0.021
Presentation TR velocity (\pm SD), cm/s	2.7 (\pm 0.4)	3.2 (\pm 0.5)	0.030
Presentation IVC diameter, cm	1.9 (\pm 0.6)	2.1 (\pm 0.3)	0.36
Repeat LV ejection fraction (\pm SD)	63 (\pm 9)	58 (\pm 9)	0.23
Repeat TR velocity (\pm SD), cm/s	2.5 (\pm 0.6)	2.6 (\pm 0.4)	0.80
Repeat IVC diameter, cm	1.7 (\pm 0.6)	1.7 (\pm 0.4)	0.92
Follow-up time for repeat echocardiography (\pm SD), days	61 (\pm 55)	86 (\pm 115)	0.60
Hospital stay (\pm SD), days	7 (\pm 4)	11 (\pm 5)	0.033
Severe CHF	2	6	0.0016
Intubation	0	5	0.0003
IABP	0	3	0.0071
CPR	0	1	0.14
Severe CHF, IABP, or CPR	2	7	0.0002
LV thrombus	1	0	0.48
LV outflow tract obstruction	2	0	0.31
Follow-up after event (months)	19.3 \pm 13.9	7.0 \pm 6.3	0.026
Recurrence	0	1	0.14
Death	1	2	NS

CHF = congestive heart failure; CPR = cardiopulmonary resuscitation; IABP = intra-aortic balloon pump; IVC = inferior vena cava; LV = left ventricular; NS = not significant; RV = right ventricular; TR = tricuspid valve regurgitation.

1/3 cas : atteinte du VD

FEVG **diminuée**

Plus de complication **isolée / associées**

Durée d'hospitalisation allongée

Si pas d'atteinte initiale

=> pas d'atteinte au cours de l'évolution

ETT




End diastole

End systole



Normalisation de la FEVG dans le temps




al ballooning

End diastole



End systole




IRM cardiaqu

ventricular ballooning with sparing of apical and basal region


End diastole




End systole




End systole





Basal myocardium




Middle myocardium




Apical myocardium



ŒDÈME




MYOCARDIQUE



KT cardiaque


Contraction basale
hyperdynamique
Akinésie segment moyen et apical



Contraction basale et apicale
hyperdynamique
Akinésie segment moyen

Biomarqueurs cardiaques

Troponine T



BNP/Troponine T : aide pour **SCA ST**

Table 2 Characteristics of apical ballooning syndrome and ST-elevation myocardial infarction controls

Variables	STEMI (N=50)	ABS (N=50)	P
Age (years)	69.0 ± 12.4	68.7 ± 11.9	
Men	3 (6%)	3 (6%)	
Hypertension	31 (62%)	35 (70%)	
Diabetes mellitus	7 (14%)	5 (10%)	
Smoking	23 (47%)	16 (33%)	
Hypercholesterolemia	27 (63%)	22 (44%)	
Ejection fraction by echocardiogram (%)	52.0 (40.0, 63.5)	37.0 (30.0, 52.0)	<
BNP (pg/ml)	168.5 (63.0, 515.0)	554.5 (233.0, 937.0)	<
Admission troponin T (ng/ml)	0.2 (0.1, 0.9)	0.2 (0.1, 0.6)	
Peak troponin T (ng/ml)	2.8 (1.0, 6.5)	0.5 (0.2, 0.8)	<
Peak CK-MB (ng/ml)	94.9 (18.4, 182.6)	12.3 (7.9, 25.3)	<
BNP/admission troponin T ratio	649.3 (146.5, 5405.4)	2069.1 (582.6, 7000.0)	<
BNP/peak troponin T ratio	97.4 (17.9, 264.7)	1089.4 (446.7, 3334.8)	<

Biomarqueurs cardiaques

BNP/Troponine T : aide pour **SCA ST-** ?

Table 3 Characteristics of apical ballooning syndrome and non-ST-elevation myocardial infarction controls

Variables	NSTEMI (N=25)	ABS (N=25)	P
Age (years)	69.0 ± 11.4	69.3 ± 11.2	
Male	3 (12%)	3 (12%)	
Hypertension	18 (78%)	17 (68%)	
Diabetes mellitus	3 (12%)	2 (8%)	
Hyperlipidemia	11 (48%)	11 (44%)	
Hypercholesterolemia	14 (64%)	11 (44%)	
Ejection fraction by echocardiogram (%)	55.0 (50.0, 60.0)	32.0 (28.0, 50.0)	<
B-type natriuretic peptide (pg/ml)	198.0 (105.0, 283.0)	561.0 (140.0, 919.0)	
Admission troponin T (ng/ml)	0.3 (0.1, 0.6)	0.2 (0.1, 0.6)	
Peak troponin T (ng/ml)	0.6 (0.3, 1.6)	0.5 (0.3, 0.6)	
CK-MB (ng/ml)	24.7 (10.1, 46.0)	11.9 (8.1, 25.5)	
Admission troponin T ratio	1023.3 (243.8, 2358.3)	2114.3 (620.2, 7000.0)	
Peak troponin T ratio	243.8 (123.5, 600.0)	1059.1 (500.0, 1938.2)	

Catécholamines endogènes



	<u>Patients with Stress Cardiomyopathy (N= 13)</u>			Patients with Killip Class III Myocardial Infarction (N= 13)		
	Day 1 or 2	Day 3, 4, or 5	Day 7, 8, or 9 <i>median (interquartile range)</i>	Day 1 or 2	Day 3, 4, or 5	Day 7, 8, or 9 <i>median (interquartile range)</i>
Catecholamine precursor (pg/ml)						
Dopamine	2859 (2721–2997)†	2495 (2386–2761)†	1656 (1065–2011)	1282 (1124–1656)	1203 (1193–1873)	907 (749–1065)
Catecholamines (pg/ml)						
Norepinephrine	37	1264 (916–1374)†	1044 (733–1118)†	348 (180–550)	376 (275–476)	330 (220–385)
Epinephrine	169	2284 (1709–2910)†	1573 (1235–2589)†	1142 (525–1252)	1100 (914–1320)	829 (727–914)
Vanillylmandelic acid	15	111 (106–146)†	77 (63–110)	56 (47–77)	61 (46–77)	61 (61–77)
Neuronal metabolites (pg/ml)						
Metanephrine		178 (140–187)	509 (385–789)	659 (590–738)§	106 (89–124)	203 (177–213)
Normetanephrine		216 (130–319)	456 (229–569)	661 (551–696)§	160 (145–170)	196 (181–209)
Peptides (pg/ml)						
Brain natriuretic peptide		186 (162–236)§	185 (158–214)†	136 (90–182)§	77 (60–90)	69 (61–71)
Pro-B-type natriuretic peptide		1033 (805–1783)§	450 (205–684)	142 (72–236)	264 (192–483)	268 (249–574)

Facteurs déclenchants

Stress physique Stress psychologique

Physical (n = 57)

Acute respiratory failure (n = 15)

Exacerbation of chronic obstructive pulmonary disease*
Pulmonary embolism
Laryngeal obstruction from neoplasm
Respiratory distress from influenza
Acute epiglottitis requiring intubation

Central nervous system conditions (n = 10)

Subarachnoid hemorrhage
Brain contusion from accidental fall
Ruptured cerebral aneurysm
Vasculitis
Migraine headache
Seizure
Brain abscess

Malignancy† (n = 6)

Advanced or metastatic cancer
Chemotherapy for metastatic colon or esophageal cancer
Metastatic carcinoid tumor

Infection (n = 3)

Urosepsis
Spinal fusion wound infection
Peritonitis from ischemic bowel

Post-surgical/fracture (n = 8)

Hysterectomy and bilateral oophorectomy
Knee arthroplasty
Discectomy and T12-S1 fusion for scoliosis‡
Cholecystectomy
Decompression of spinal stenosis
Pericardiocentesis
Hip fracture

Other (n = 15)

Nosebleed treated with phenylephrine
Accidental home insulin overdose
Intentional Phenergan overdose
Dobutamine stress test
Gastrointestinal bleeding/gastroenteritis with dehydration
Acute rejection of renal transplant
Diabetic/nondiabetic gastroparesis
Anorexia with profound weight loss
Allergic drug reaction
Prolonged viral illness/dehydration
Hypertensive crisis
Withdrawal from alcohol

Critères diagnostiques

MAYO CLINIC

transient hypokinesis, akinesis, or dyskinesis of the left ventricular mid segments with or without apical involvement; the regional wall motion abnormalities extend beyond a single epicardial vascular distribution; a stressful trigger is often, but not always present.

Absence of obstructive coronary disease or angiographic evidence of acute plaque rupture. †

New electrocardiographic abnormalities (either ST-segment elevation and/or T-wave inversion) or modest elevation in cardiac troponin.

Absence of:

Pheochromocytoma
Myocarditis

In the absence of the above circumstances, the diagnosis of ACS should be made with caution, and a clear stressful precipitating trigger must be sought.

There are rare exceptions to these criteria such as those patients in whom the regional wall motion abnormality is limited to a single coronary territory.

It is possible that a patient with obstructive coronary atherosclerosis may also develop ACS. However, this is very rare in our experience and in the published literature, perhaps because such cases are misdiagnosed as an acute coronary syndrome.

SCA +++

et al., Am Heart J, 2008

JAPANESE CIRCULATION SOCIETY

Table 1 Guidelines for Diagnosis of Takotsubo (Ampulla) Cardiomyopathy

I. Definition

Takotsubo (ampulla) cardiomyopathy is a disease exhibiting an acute left ventricular apical ballooning of unknown etiology. In this disease, the left ventricle takes on the shape of a "takotsubo" (Japanese octopus trap). There is nearly complete resolution of the apical akinesis in the majority of the patients within a month. The contraction abnormality occurs in the left ventricle, but involvement of the right ventricle is observed in some cases. A dynamic obstruction of the left ventricular outflow tract (pressure gradient difference, acceleration of blood flow, or systolic cardiac murmurs) is also observed. Note: There are patients, such as cerebrovascular patients, who have an apical systolic ballooning similar to that of takotsubo cardiomyopathy, but with a known cause. Such patients are diagnosed as "cerebrovascular disease with takotsubo-like myocardial dysfunction" and are differentiated from idiopathic cases.

II. Exclusion criteria

The following lesions and abnormalities from other diseases must be excluded in the diagnosis of takotsubo (ampulla) cardiomyopathy.

A. Significant organic stenosis or spasm of a coronary artery. In particular, acute myocardial infarction due to a lesion of the anterior descending branch of the left coronary artery, which perfuses an extensive territory including the left ventricular apex (An urgent coronary angiogram is desirable for imaging during the acute stage, but coronary angiography is not necessary during the chronic stage to confirm the presence or absence of a significant stenotic lesion or a lesion in the abnormal pattern of ventricular contraction).

- B. Cerebrovascular disease
- C. Pheochromocytoma
- D. Viral or idiopathic myocarditis

Note: For the exclusion of coronary artery lesions, coronary angiography is required. Takotsubo-like myocardial dysfunction could occur with diseases such as cerebrovascular disease and pheochromocytoma.

III. References for diagnosis

A. Symptoms: Chest pain and dyspnea similar to those in acute coronary syndrome. Takotsubo cardiomyopathy can occur without symptoms.

B. Triggers: Emotional or physical stress may trigger takotsubo cardiomyopathy, but it can also occur without a clear precipitant trigger.

C. Age and gender difference: Known tendency to increase in the elderly, particularly females.

D. Ventricular morphology: Apical ballooning and its rapid improvement in the ventriculogram and echocardiogram.

E. Electrocardiogram: ST segment elevations might be observed immediately after the onset. Thereafter, in a typical case, the T-wave becomes progressively more negative in multiple leads, and the QT interval prolongs. These changes occur gradually, but a negative T-wave may continue for several months. During the acute stage, abnormal Q-waves and ST-T changes in the QRS voltage might be observed.

F. Cardiac biomarkers: In a typical case, there is only modest elevations of serum levels of cardiac enzymes and troponin.

G. Myocardial radionuclear study: Abnormal findings in myocardial scintigraphy are observed in some cases.

H. Prognosis: The majority of the cases rapidly recover, but some cases suffer pulmonary edema and other sequelae.

Kawai et al, Circ Journal

Complications

Table 2

Clinical outcomes

Outcome	n (%)
Complication	
Heart failure	22 (26%)
Intra-aortic balloon pumping	4 (5%)
Mechanical ventilation	2 (2%)
Interventricular pressure gradient	11 (13%)
Severe acute mitral regurgitation	9 (11%)
Embolism	3 (4%)
Ventricular tachycardia/fibrillation	3 (4%)
Cardiogenic shock	9 (11%)
In-hospital death	2 (2%)
Number of above complications	
1	20 (24%)
≥2	14 (16%)

Pronostic


COURT TERME

Characteristics	General admissions, n (%)	TTC, n (%)
Total admissions	33 506 402	6837
Age, y		
18-34	6 556 830 (19.6)	127 (1.9)
35-49	5 588 174 (16.7)	581 (8.5)
50-64	7 382 129 (22)	1975 (28.9)
65-79	8 038 673 (24)	2952 (43.2)
≥ 80	5 963 187 (17.8)	1202 (17.6)
Sex		
Male	13 271 083 (39.7)	660 (9.7)
Female	20 173 088 (60.3)	6178 (90.4)
Race		
White	18 957 769 (56.5)	4606 (67.4)
Black	3 445 928 (10.3)	300 (4.4)
Hispanic	2 638 251 (7.9)	298 (4.3)
Asian	680 357 (2.0)	76 (1.1)
Native American	173 273 (0.5)	43 (0.6)
Others	882 716 (2.6)	103 (1.5)
Unknown	6 750 699 (20.1)	1413 (20.7)
Outcomes		
Died	787 814 (2.4)	151 (2.2)


$p < .05$ using χ^2 test. See text for details.

81,4% causes non-cardiaques

LONG TERME






Physiopathologie



???


Rappel 1 : Synthèse catécholamines endogènes



★ Régulation par la concentration intra cytoplasmique de NAD

Sympathomimétiques indirects : adrénaline, amphétamines
Induisent la libération de NAD par ses sites de stockage

Rappel 2 : Récepteurs adrénérgiques



cepteur béta 2 peut être couplé à une G protéine **activatrice OU inhibitrice**

Rappel 2 : Récepteurs adrénérgiques

ÉPINEPHRINE	ALPHA 1	+++ →	Fibres musculaires lisses	Vasculaires : vasoconstriction
	BÉTA 1	+++ →	Cardiaque	C+ I+ D+ B+
	BÉTA 2	++ →	Vaisseaux Bronches	Relaxation FML vasculaires broncho dilatation
NÉPHRÉALINE	ALPHA 1	+++ →	Fibres musculaires lisses	Vasculaires : vasoconstriction
	BÉTA 1	+ →	Cardiaque	C+ I+ D+ B+
DOPAMINE	BÉTA 1	+++ →	Cardiaque	C+ I+ D+ B+
	BÉTA 2	+ →	Vaisseaux Bronches	Relaxation FML vasculaires broncho dilatation

Concentration plasmatiques élevées en catécholamines

Catécholamines ENDOGÈNES

Augmentation de la **synthèse**

Pathologique :
Phéochromocytome

Physiologique :
Stress physique /
psychique

Augmentation de la
libération

Libération par les sites
de stockage :
Cocaïne
Amphétamines...

CMP liée au
phéochromocytome
1ère description 1989

Takotsubo

Catécholamines EXOGÈNES

Injection de catécholamines :
AD
NAD
Isoprénaline
Dobutamine

CMP liée aux catécholamines
1ère description 1950's

EDITORIAL REVIEW

Catecholamine Cardiotoxicity

Cardiomyopathie associées aux catécholamines





Fig. 3. The necrotic cardiac muscle fibers are separated from normal fibers by mucoïd edema. There is early necrosis. PAS × 120.

Cardiotoxic effect of epinephrine and norepinephrine

Soon after the discovery of epinephrine, Josué showed that this agent produces myocardial hypertrophy [53]. The epinephrine-induced myocardial alteration was designated as myocardial necrosis [80] or myocardial degeneration [38]. In the late fifties, several publications appeared indicating that norepinephrine is also cardiotoxic [62, 72, 112, 121]. The experimental works focused attention to the human myocardial changes following therapeutic norepinephrine administration [122].

Hypothèse 1 : « cardiac stunning »

C'est à dire : mécanisme de protection du cardiomyocyte pour épargner les régions affectées par l'ischémie et les arythmies



hypothèse 1 : « cardiac stunning »


Majoration des tensions pariétales VG

Augmentation des contraintes physiques locales
Supra-physiologique

Hypertrophie VG
Mécanisme compensateur de la redistribution des contraintes

Augmentation de la demande contractile myocardique

Augmentation de la demande d'NRJ



Shao et al., Int J Cardiology

modèle de rat : pas les mêmes résultats avec E/NE...

« cardiac stunning »

Déséquilibre entre demande et capacité

Shao et al., Int J Cardiology, 2014

Hypothèse 2 : défaut de perfusion myocardique initial

Spasmes coronaires et défaut de la microvascularisation

Thrombus coronaire dissout

IRM : défauts de rehaussement

Spasmes pendant coro
Variant anatomique?

Défauts de perfusion :
Conséquence

Pas de défaut de perfusion initial dans les modèles murins

Pas de corrélation fonctionnelle
Zone touchée trop étendue

Spasme des coronaires principales

REGULATION


Modèle de cardiopathie « ischémique »...? :

inadéquation entre demande et apports suffisants en O₂ et nutriments

zones d'ischémies locales

- altération de la conduction / œdème
- redistribution des contraintes physiques sur les zones non- touchées

hypothèse 3 : excès de relargage **local** de catécholamines




- Apports des catécholamines
- Système sympathique
 - NE >> E
 - Sang
 - Zones de stockage cardiaques

Modèles murins : majoritairement des catécholamines **LOCALEMENT** ne suffit pas

Gradient de répartition de NE

hypothèse 4 : « beta2 adrenoreceptor/Gi-pathway hypothesis »


physiologique
RÉNALINE



non physiologique
concentrations
supraphysiologiques
RÉNALINE



est aussi sensible AUSSI par NE
est sensible MEME quand inhibition de la Gi (toxine
tussive)



hypothèse 5 : carence oestrogénique

STRESS, NEUROTRANSMITTERS, AND HORMONES

Catecholamines and Estrogen Are Involved in the Pathogenesis of Emotional Stress-induced Acute Heart Attack

**Takashi Ueyama,^a Ken Kasamatsu,^b Takuzo Hano,^b
Yoshihiro Tsuruo,^a and Fuminobu Ishikura^c**

*^aDepartment of Anatomy and Cell Biology and ^bDepartment of Cardiovascular Medicine,
Wakayama Medical University School of Medicine, Wakayama, Japan*

*^cDivision of Functional Diagnostic Science, Osaka University Graduate School
of Medicine, Suita, Japan*

INCIDENCE MAXIMALE CHEZ LES FEMMES MÉNOSÉES

Majoration de la sensibilité des Béta récepteurs

Diminution de la concentration basale de catécholamine

traitement

port risque...?

Box 2 Differences between Takotsubo syndrome and acute myocarditis


Category	Takotsubo syndrome	Acute myocarditis
Gender and age	90% female. Majority >50 years and post-menopausal.	No sex prevalence. More frequent in the young.
Preceding events	Stressor trigger identifiable in ~70% of cases.	Symptoms and signs of infection often present (fever, chills, headache, muscle aches, general malaise, cough, nausea, vomiting, diarrhoea).
Cardiac symptoms	Chest pain, dyspnoea, palpitations.	Chest pain, dyspnoea, peripheral oedema, fatigue, and palpitations.
Clinical signs	Pericardial rub rare.	Pericardial rub may be present.
ECG at admission	ST changes such as ST-segment elevation or non ST-segment elevation. Deep T wave inversion. QT prolongation. Rarely normal.	ST-segment elevation or depression, negative T-wave, bundle branch block, atrioventricular block, low voltage, and/or ventricular arrhythmias. Normal in several cases.
Cardiac enzymes	Low/moderate troponin rise. Discrepancy between the large amount of dysfunctional myocardium and peak troponin level.	Frequently significant troponin rise, proportional to the hypokinetic area. Normal in several cases.
Other biomarkers	C-reactive protein (CRP) mildly elevated unless infective trigger. BNP moderately or significantly elevated.	Erythrocyte sedimentation rate and CRP elevated. BNP basically elevated. Acute viral serology may be detected.
Echocardiography	Apical ballooning, anatomical variants, 'circumferential pattern', left ventricular outflow tract obstruction (LVOTO), right ventricular (RV) involvement, transient mitral regurgitation.	Localized or diffuse wall motion abnormalities of LV and/or RV dilatation, increased wall thickness, pericardial effusion.
Cardiac magnetic resonance imaging	High T2 signal intensity (oedema), late gadolinium enhancement (LGE) usually absent acutely. If present acutely patchy LGE which usually resolves at follow-up. Absence of typical infarct LGE pattern.	High T2 signal intensity (oedema), LGE with non-ischaemic distribution (often epicardial). Absence of typical infarct LGE pattern.
Histological findings	Contraction band necrosis.	Infiltration of many inflammatory cells. Interstitial oedema.
Viral genome, separation of virus, or identification of virus by antibody titre	Rare and usually absent where measured.	Often positive.
Prognosis	50% of cases have acute complications, 4–5% mortality.	Variable but majority full recovery. Highest mortality with fulminant myocarditis.
Therapy	Supportive.	Supportive. Immunosuppression in severe cases if giant cell myocarditis suspected.

aitement

EVG > 45%
rien

EVG 35 – 45 %
B- +/- IEC

Surveillance
Vérifier
normalisation FEVG



B-
FEVG < 45%
Arhythmies A/
LVOTO+ / HoT

Thrombus
apical ?

Choc
cardiogénique
ECMO

Take Home Messages

Cardiomyopathie transitoire réversible

- Induite par stress physique / psychologique
- Akinésie / hypokinésie apicale et antéro-apicale du VG +/- VD

Incidence maximale chez les femmes ménopausées

Physiopathologie complexe – plusieurs phénomènes intriqués

- Hyperexcitabilité sympathique
- Cardiac stunning...

Traitement :

- Pas d'inotrope + / vasodilatateur
- Dépend de la sévérité